Incorporation of therapeutically modified bacteria into Gut microbiota inhibits obesity

Journal of Clinical Investigation

Volumn 124, Issue 8, 2014, Pages 3391-3406

  Chen, Zhongyi ^a   Guo, Lilu ^a   Zhang, Yongqin ^a   Walzem, Rosemary L ^b   Pendergast, Julie S ^c   Printz, Richard L ^c   Morris, Lindsey C ^c   Matafonova, Elena ^a   Stien, Xavier ^a   Kang, Li ^d   Coulon, Denis ^e   McGuinness, Owen P ^d   Niswender, Kevin D ^c,d,f   Davies, Sean S ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c Division of Endocrinology Metabolism and Diabetes University of Colorado Anschutz Medical Campus   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f Veterans Administration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DRINKING WATER; N ACYLPHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE; PROBIOTIC AGENT; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ARABIDOPSIS PROTEIN; DNA BINDING PROTEIN; MHF2 PROTEIN, ARABIDOPSIS; PHOSPHATIDYLETHANOLAMINE N-ACYLTRANSFERASE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENERGY EXPENDITURE; ESCHERICHIA COLI; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; FECES MICROFLORA; FOOD INTAKE; GENE EXPRESSION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTESTINE FLORA; LIGHT DARK CYCLE; LIPID DIET; LIPID STORAGE; MALE; MOUSE; MOUSE MODEL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; WEIGHT GAIN; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; DIGESTIVE SYSTEM; DISEASE MODEL; EATING; FEMALE; GENETICS; HUMAN; LIVER; METABOLISM; MICROBIOLOGY; MICROFLORA; PATHOLOGY;

ACYLTRANSFERASES; ANIMALS; ARABIDOPSIS PROTEINS; DIET, HIGH-FAT; DIGESTIVE SYSTEM; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; EATING; ESCHERICHIA COLI; FEMALE; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICROBIOTA; OBESITY; PHOSPHATIDYLETHANOLAMINES; RECOMBINANT PROTEINS; WEIGHT GAIN;

EID: 84905495117     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72517     Document Type: Article

References (76)

1. Lam DW, Le Roith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes. 2012;19(2):93-96.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. PRevalence and trends in obesity among us adults, 1999-2008. JAMA. 2010;303(3):235-241.
3. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr. 2001;21:323-341.
4. Stunkard A, Mc L-HM. The results of treatment for obesity: a review of the literature and report of a series. AMA Arch Intern Med. 1959;103(1):79-85.
5. Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes. 1989;13(2):123-136.
6. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes. 1989;13(suppl 2):39-46.
7. Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? J Obes. 2012;2012:879151.
8. Wang Z, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63.
9. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031.
10. Turnbaugh PJ, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480-484.
11. Vijay-Kumar M, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328(5975):228-231.
12. Cani PD, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470-1481.
13. Membrez M, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J. 2008;22(7):2416-2426.
14. Fu J, et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem. 2007;282(2):1518-1528.
15. Gillum MP, et al. N-acylphosphatidylethanolamine, a gut-derived circulating factor induced by fat ingestion, inhibits food intake. Cell. 2008;135(5):813-824.
16. Hansen HS, Diep TA. N-acylethanolamines, anandamide and food intake. Biochem Pharmacol. 2009;78(6):553-560.
17. Petersen G, et al. Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochim Biophys Acta. 2006;1761(2):143-150.
18. Schwartz GJ, et al. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab. 2008;8(4):281-288.
19. Rodriguez de Fonseca F, et al. An anorexic lipid mediator regulated by feeding. Nature. 2001;414(6860):209-212.
20. Nielsen MJ, Petersen G, Astrup A, Hansen HS. Food intake is inhibited by oral oleoylethanolamide. J Lipid Res. 2004;45(6):1027-1029.
21. Terrazzino S, et al. Stearoylethanolamide exerts anorexic effects in mice via down-regulation of liver stearoyl-coenzyme A desaturase-1 mRNA expression. FASEB J. 2004;18(13):1580-1582.
22. Srisai D, et al. Characterization of the hyperphagic response to dietary fat in the MC4R knockout mouse. Endocrinology. 2011;152(3):890-902.
23. Guzman M, Lo Verme J, Fu J, Oveisi F, Blazquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-α). J Biol Chem. 2004;279(27):27849-27854.
24. Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005;48(8):1147-1153.
25. Thabuis C, et al. Lipid transport function is the main target of oral oleoylethanolamide to reduce adiposity in high-fat-fed mice. J Lipid Res. 2011;52(7):1373-1382.
26. Cluny NL, Keenan CM, Lutz B, Piomelli D, Sharkey KA. The identification of peroxisome proliferatoractivated receptor α-independent effects of oleoylethanolamide on intestinal transit in mice. Neurogastroenterol Motil. 2009;21(4):420-429.
27. Aviello G, et al. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J Mol Med (Berl). 2008;86(4):413-422.
28. Fu J, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature. 2003;425(6953):90-93.
29. Thabuis C, Destaillats F, Landrier JF, Tissot-Favre D, Martin JC. Analysis of gene expression pattern reveals potential targets of dietary oleoylethanolamide in reducing body fat gain in C3H mice. J Nutr Biochem. 2010;21(10):922-928.
30. Lo Verme J, et al. The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-19.
31. Wang X, Miyares RL, Ahern GP. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J Physiol. 2005;564(Pt 2):541-547.
32. Faure L, et al. Discovery and characterization of an Arabidopsis thaliana N-acylphosphatidylethanolamine synthase. J Biol Chem. 2009;284(28):18734-18741.
33. Guo L, Amarnath V, Davies SS. A liquid chromatographytandem mass spectrometry method for measurement of N-modified phosphatidylethanolamines. Anal Biochem. 2010;405(2):236-245.
34. Bulat E, Garrett TA. Putative N-acylphosphatidylethanolamine synthase from Arabidopsis thaliana is a lysoglycerophospholipid acyltransferase. J Biol Chem. 2011;286(39):33819-33831.
35. Horn CC, De Jonghe BC, Matyas K, Norgren R. Chemotherapy-induced kaolin intake is increased by lesion of the lateral parabrachial nucleus of the rat. Am J Physiol Regul Integr Comp Physiol. 2009;297(5):R1375-R1382.
36. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070-11075.
37. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023.
38. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008;3(4):213-223.
39. Montague CT, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903-908.
40. Rolland V, et al. Leptin receptor gene in a large cohort of massively obese subjects: no indication of the fa/fa rat mutation. Detection of an intronic variant with no association with obesity. Obes Res. 1998;6(2):122-127.
41. Dubern B, Clement K. Leptin and leptin receptorrelated monogenic obesity. Biochimie. 2012;94(10):2111-2115.
42. Leiter EH, Strobel M, O'Neill A, Schultz D, Schile A, Reifsnyder PC. Comparison of two new mouse models of polygenic type 2 diabetes at the Jackson Laboratory, NONcNZO10Lt/J and TALLYHO/JngJ. J Diabetes Res. 2013;2013:165327.
43. Kim JH, et al. Genetic analysis of a new mouse model for non-insulin-dependent diabetes. Genomics. 2001;74(3):273-286.
44. Kim JH, Saxton AM. The TALLYHO mouse as a model of human type 2 diabetes. Methods Mol Biol. 2012;933:75-87.
45. Kim JH, et al. Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. J Endocrinol. 2006;191(2):437-446.
46. Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci U S A. 1997;94(6):2238-2242.
47. Ueda N, Tsuboi K, Uyama T. N-acylethanolamine metabolism with special reference to N-acylethanolaminehydrolyzing acid amidase (NAAA). Prog Lipid Res. 2010;49(4):299-315.
48. Gaetani S, Oveisi F, Piomelli D. Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology. 2003;28(7):1311-1316.
49. Oveisi F, Gaetani S, Eng KT, Piomelli D. Oleoylethanolamide inhibits food intake in freefeeding rats after oral administration. Pharmacol Res. 2004;49(5):461-466.
50. Fu J, Kim J, Oveisi F, Astarita G, Piomelli D. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol. 2008;295(1):R45-R50.
51. Syed SK, et al. Regulation of GPR119 receptor activity with endocannabinoid-like lipids. Am J Physiol Endocrinol Metab. 2012;303(12):E1469- E1478.
52. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagonlike peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes. 2009;58(5):1058-1066.
53. Mack CM, et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond). 2006;30(9):1332-1340.
54. Tatarkiewicz K, Sablan EJ, Polizzi CJ, Villescaz C, Parkes DG. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor. Am J Physiol Regul Integr Comp Physiol. 2014;306(7):R490-R498.
55. Perreault M, et al. Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice. Diabetes Obes Metab. 2010;12(3):234-245.
56. Harrington WW, et al. The effect of PPARα, PPARδ, PPARγ, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice. PPAR Res. 2007;2007:97125.
57. Larsen PJ, et al. Differential influences of peroxisome proliferator-activated receptors γ and -α on food intake and energy homeostasis. Diabetes. 2003;52(9):2249-2259.
58. Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D. Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci. 2005;62(6):708-716.
59. Ahern GP. Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem. 2003;278(33):30429-30434.
60. Ho WS, Barrett DA, Randall MD. 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol. 2008;155(6):837-846.
61. Astrup A. The relevance of increased fat oxidation for body-weight management: metabolic inflexibility in the predisposition to weight gain. Obes Rev. 2011;12(10):859-865.
62. Schmidt SL, Kealey EH, Horton TJ, VonKaenel S, Bessesen DH. The effects of short-term overfeeding on energy expenditure and nutrient oxidation in obesity-prone and obesity-resistant individuals. Int J Obes (Lond). 2013;37(9):1192-1197.
63. Brown WH, et al. Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism. Proc Natl Acad Sci U S A. 2012;109(37):14966-14971.
64. Buddenborg C, Daudel D, Liebrecht S, Greune L, Humberg V, Schmidt MA. Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier. Int J Med Microbiol. 2008;298(1-2):105-114.
65. Majander K, et al. Extracellular secretion of polypeptides using a modified Escherichia coli flagellar secretion apparatus. Nat Biotech. 2005;23(4):475-481.
66. Blight MA, Holland IB. Heterologous protein secretion and the versatile Escherichia coli haemolysin translocator. Trends Biotechnol. 1994;12(11):450-455.
67. Huibregtse IL, et al. Genetically modified Lactococcus lactis for delivery of human interleukin-10 to dendritic cells. Gastroenterol Res Pract. 2012;2012:639291.
68. Mileykovskaya E, et al. Phosphatidic acid and N- acylphosphatidylethanolamine form membrane domains in Escherichia coli mutant lacking cardiolipin and phosphatidylglycerol. J Biol Chem. 2009;284(5):2990- 3000.
69. Kang JH, Yun SI, Park MH, Park JH, Jeong SY, Park HO. Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS One. 2013;8(1):e54617.
70. Fak F, Backhed F. Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/-mice. PLoS One. 2012;7(10):e46837.
71. Lee HY, et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006;1761(7):736-744.
72. An HM, et al. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat dietinduced obese rats. Lipids Health Dis. 2011;10:116.
73. Andersson U, et al. Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse. Benef Microbes. 2010;1(2):189-196.
74. Capone KA, Dowd SE, Stamatas GN, Nikolovski J. Diversity of the human skin microbiome early in life. J Invest Dermatol. 2011;131(10):2026-2032.
75. Swanson KS, et al. Phylogenetic and gene-centric metagenomics of the canine intestinal microbiome reveals similarities with humans and mice. ISME J. 2011;5(4):639-649.
76. DeSantis TZ, et al. Greengenes, a chimerachecked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006;72(7):5069-5072.